Clinical Trial Update: Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the efficacy, safety, tolerability and pharmacokinetics of BIBN 4096 BS versus placebo for treating a single acute migraine attack.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• BIBN 4096 BS

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Migraine Disorders | Phase 2 | Status: COMPLETED